KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53774

language	eng
Author	Rahman Mohammed Tanjimur Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan NAKAYAMA, Kentaro Rahman Munmun Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan Katagiri Hiroshi Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan Katagiri Atsuko Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan ISHIBASHI, Tomoka ISHIKAWA, Masako SATO, Emi IIDA, Koji Nakayama Naomi Department of Biocehmistory, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan Ishikawa Noriyuki Department of Organ Pathology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan Miyazaki Kohji Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan
Subject	type II ovarian carcinoma; KRAS; MAPK1; gene amplification; survival; MEK inhibitor
Journal Title	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume	14
Issue	7
Start Page	13748
End Page	13762
ISSN	1422-0067
Published Date	2013-07
DOI	10.3390/ijms140713748
PubMed ID	23820584
Publisher	MDPI AG
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	This study was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology in Japan.